{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:31:45Z","timestamp":1786991505797,"version":"build-2736575974"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jaut.2019.04.005","type":"journal-article","created":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T01:29:43Z","timestamp":1556069383000},"page":"26-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature"],"prefix":"10.1016","volume":"101","author":[{"given":"Christopher L.","family":"Bowlus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Xiang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung H.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep S.","family":"Dhaliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Frank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Vierling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Eric","family":"Gershwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2019.04.005_bib1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.04.005_bib2","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","article-title":"Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid","volume":"136","author":"Kuiper","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.04.005_bib3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib4","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2019.04.005_bib5","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.04.005_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.04.005_bib7","first-page":"84","article-title":"Combined treatment with ursodeoxycholic acid and prednisone in primary biliary cirrhosis","volume":"44","author":"Wolfhagen","year":"1994","journal-title":"Neth. J. Med."},{"key":"10.1016\/j.jaut.2019.04.005_bib8","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0168-8278(98)80254-7","article-title":"Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study","volume":"29","author":"Wolfhagen","year":"1998","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2019.04.005_bib9","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM199005173222003","article-title":"A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis","volume":"322","author":"Wiesner","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.04.005_bib10","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep.20897","article-title":"Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis","volume":"42","author":"Combes","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.mcg.0000177235.36640.21","article-title":"Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid","volume":"39","author":"Treiber","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"key":"10.1016\/j.jaut.2019.04.005_bib12","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.510310209","article-title":"Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid","volume":"31","author":"Angulo","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib13","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/hep.20646","article-title":"Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial","volume":"41","author":"Rautiainen","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib14","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/S0016-5085(99)70351-3","article-title":"Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial","volume":"117","author":"Leuschner","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.04.005_bib15","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/S0168-8278(18)30293-9","article-title":"Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid","volume":"68","author":"Hirschfield","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jaut.2019.04.005_bib16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.gtc.2017.05.015","article-title":"Janus Kinase antagonists and other novel small molecules for the treatment of Crohn's disease","volume":"46","author":"Boland","year":"2017","journal-title":"Gastroenterol. Clin. N. Am."},{"key":"10.1016\/j.jaut.2019.04.005_bib17","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.autrev.2014.01.041","article-title":"The diagnosis of primary biliary cirrhosis","volume":"13","author":"Bowlus","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2019.04.005_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.gastro.2004.11.005","article-title":"Bacterial CpG induces hyper-IgM production in CD27(+) memory B cells in primary biliary cirrhosis","volume":"128","author":"Kikuchi","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.04.005_bib19","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1002\/hep.23238","article-title":"B-cell depletion with anti-CD20 ameliorates autoimmune cholangitis but exacerbates colitis in transforming growth factor-beta receptor II dominant negative mice","volume":"50","author":"Moritoki","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib20","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.04.005_bib21","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/nrrheum.2009.100","article-title":"Connective tissue diseases: the conundrum of B cell depletion in SLE","volume":"5","author":"Sanz","year":"2009","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jaut.2019.04.005_bib22","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1182\/blood-2007-02-068999","article-title":"Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura","volume":"110","author":"Stasi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.04.005_bib23","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood.V98.4.952","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura","volume":"98","author":"Stasi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jaut.2019.04.005_bib24","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(01)06573-4","article-title":"Treatment of childhood autoimmune haemolytic anaemia with rituximab","volume":"358","author":"Quartier","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jaut.2019.04.005_bib25","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.jaut.2019.04.005_bib26","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.24748","article-title":"Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"55","author":"Tsuda","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib27","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ajg.2013.51","article-title":"B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid","volume":"108","author":"Myers","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jaut.2019.04.005_bib28","article-title":"Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial","author":"Khanna","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib29","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.cld.2018.03.002","article-title":"The genetics and epigenetics of primary biliary cholangitis","volume":"22","author":"Tanaka","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.jaut.2019.04.005_bib30","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/hep.26979","article-title":"IL-12\/Th1 and IL-23\/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy","volume":"59","author":"Yang","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.2009.03898.x","article-title":"Imbalance between T helper type 17 and T regulatory cells in patients with primary biliary cirrhosis: the serum cytokine profile and peripheral cell population","volume":"156","author":"Rong","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.04.005_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2249.2009.03947.x","article-title":"Periductal interleukin-17 production in association with biliary innate immunity contributes to the pathogenesis of cholangiopathy in primary biliary cirrhosis","volume":"157","author":"Harada","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.04.005_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074225","article-title":"Identification of potential cytokine pathways for therapeutic intervention in murine primary biliary cirrhosis","volume":"8","author":"Kawata","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jaut.2019.04.005_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep.28359","article-title":"Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: a proof-of-concept study","volume":"64","author":"Hirschfield","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib35","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/icb.2010.158","article-title":"CXCR3 ligands: redundant, collaborative and antagonistic functions","volume":"89","author":"Groom","year":"2011","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.jaut.2019.04.005_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jaut.2005.08.009","article-title":"Increased levels of chemokine receptor CXCR3 and chemokines IP-10 and MIG in patients with primary biliary cirrhosis and their first degree relatives","volume":"25","author":"Chuang","year":"2005","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.04.005_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13148-015-0098-9","article-title":"DNA methylation profiling of the X chromosome reveals an aberrant demethylation on CXCR3 promoter in primary biliary cirrhosis","volume":"7","author":"Lleo","year":"2015","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.jaut.2019.04.005_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1046\/j.1365-2249.2001.01391.x","article-title":"Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes","volume":"123","author":"Nishioji","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.04.005_bib39","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00795-007-0371-x","article-title":"Neutralization of CXCL10 accelerates liver regeneration in carbon tetrachloride-induced acute liver injury","volume":"40","author":"Yoneyama","year":"2007","journal-title":"Med. Mol. Morphol."},{"key":"10.1016\/j.jaut.2019.04.005_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jaut.2010.09.003","article-title":"CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation","volume":"35","author":"Hintermann","year":"2010","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.04.005_bib41","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep4.1170","article-title":"NI-0801, an anti-chemokine (C-X-C motif) ligand 10 antibody, in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid","volume":"2","author":"de Graaf","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jaut.2019.04.005_bib42","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0016-5085(03)00387-1","article-title":"Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis","volume":"124","author":"Shimoda","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.04.005_bib43","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jaut.2019.04.005_bib44","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.4049\/jimmunol.138.10.3525","article-title":"Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis","volume":"138","author":"Gershwin","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.jaut.2019.04.005_bib45","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1084\/jem.20010956","article-title":"Identification of HLA-A2-restricted CD8(+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells","volume":"195","author":"Kita","year":"2002","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2019.04.005_bib46","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI0214698","article-title":"Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis","volume":"109","author":"Kita","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.jaut.2019.04.005_bib47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/366076a0","article-title":"B70 antigen is a second ligand for CTLA-4 and CD28","volume":"366","author":"Azuma","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.jaut.2019.04.005_bib48","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1126\/science.7694363","article-title":"Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation","volume":"262","author":"Freeman","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jaut.2019.04.005_bib49","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.180.6.2049","article-title":"Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1","volume":"180","author":"Peach","year":"1994","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jaut.2019.04.005_bib50","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1074-7613(94)80021-9","article-title":"Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors","volume":"1","author":"Linsley","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.jaut.2019.04.005_bib51","first-page":"259","article-title":"SNP analysis of genes implicated in T cell proliferation in primary biliary cirrhosis","volume":"12","author":"Oertelt","year":"2005","journal-title":"Clin. Dev. Immunol."},{"key":"10.1016\/j.jaut.2019.04.005_bib52","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1002\/hep.23667","article-title":"Carriage of a tumor necrosis factor polymorphism amplifies the cytotoxic T-lymphocyte antigen 4 attributed risk of primary biliary cirrhosis: evidence for a gene-gene interaction","volume":"52","author":"Juran","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib53","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/art.24412","article-title":"CTLA4\/ICOS gene variants and haplotypes are associated with rheumatoid arthritis and primary biliary cirrhosis in the Canadian population","volume":"60","author":"Walker","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.04.005_bib54","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1136\/ard.2008.101121","article-title":"Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors","volume":"68","author":"Westhovens","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.04.005_bib55","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/art.39234","article-title":"Pediatric Rheumatology Collaborative Study and O. the Paediatric Rheumatology International Trials, Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.04.005_bib56","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jaut.2019.04.005_bib57","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/hep.26067","article-title":"Therapeutic effect of cytotoxic T lymphocyte antigen 4\/immunoglobulin on a murine model of primary biliary cirrhosis","volume":"57","author":"Dhirapong","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib58","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jaut.2019.04.005_bib59","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/RCT.0000000000000032","article-title":"Magnetic resonance elastography of liver: clinical applications","volume":"37","author":"Venkatesh","year":"2013","journal-title":"J. Comput. Assist. Tomogr."},{"key":"10.1016\/j.jaut.2019.04.005_bib60","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring System to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.04.005_bib61","first-page":"263A","article-title":"NGM282, a novel variant of FGF-19, demonstrates biologic activity in primary biliary cirrhosis patients with an incomplete response to ursodeoxycholic acid: results of a phase 2 multicenter, randomized, double blinded, placebo controlled trial","volume":"62","author":"Mayo MJ","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib62","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S2468-1253(17)30246-7","article-title":"Seladelpar (MBX-8025), a selective PPAR-delta agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study","volume":"2","author":"Jones","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jaut.2019.04.005_bib63","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12072-017-9830-1","article-title":"Primary biliary cholangitis: a comprehensive overview","volume":"11","author":"Lleo","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jaut.2019.04.005_bib64","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jaut.2019.04.005_bib65","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jaut.2019.04.005_bib66","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1053\/j.gastro.2008.11.035","article-title":"B cells suppress the inflammatory response in a mouse model of primary biliary cirrhosis","volume":"136","author":"Moritoki","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jaut.2019.04.005_bib67","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.27306","article-title":"CXCR5+ CD4+ T follicular helper cells participate in the pathogenesis of primary biliary cirrhosis","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib68","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1002\/hep.28122","article-title":"Natural killer cells regulate T cell immune responses in primary biliary cirrhosis","volume":"62","author":"Shimoda","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib69","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/cei.12415","article-title":"Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells","volume":"178","author":"Tanaka","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.jaut.2019.04.005_bib70","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaut.2011.05.009","article-title":"T cell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1","volume":"37","author":"Zhang","year":"2011","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.04.005_bib71","doi-asserted-by":"crossref","first-page":"R256","DOI":"10.1186\/ar1485","article-title":"Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis","volume":"7","author":"Gattorno","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2019.04.005_bib72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaut.2016.12.012","article-title":"Chemokine receptor CXCR3 deficiency exacerbates murine autoimmune cholangitis by promoting pathogenic CD8(+) T cell activation","volume":"78","author":"Ma","year":"2017","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.04.005_bib73","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaut.2014.01.034","article-title":"Murine autoimmune cholangitis requires two hits: cytotoxic KLRG1(+) CD8 effector cells and defective T regulatory cells","volume":"50","author":"Huang","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2019.04.005_bib74","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.21123","article-title":"Liver-targeted and peripheral blood alterations of regulatory T cells in primary biliary cirrhosis","volume":"43","author":"Lan","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib75","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/08830185.2018.1465943","article-title":"Regulatory T-cell dynamics with abatacept treatment in rheumatoid arthritis","volume":"37","author":"Langdon","year":"2018","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.jaut.2019.04.005_bib76","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.24526","article-title":"Fine phenotypic and functional characterization of effector cluster of differentiation 8 positive T cells in human patients with primary biliary cirrhosis","volume":"54","author":"Tsuda","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.jaut.2019.04.005_bib77","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S2468-1253(18)30163-8","article-title":"P.B.C.S.G. Italian and U.K.P.B.C.C. the, Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score","volume":"3","author":"Carbone","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119300861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841119300861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:22:45Z","timestamp":1760257365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841119300861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":77,"alternative-id":["S0896841119300861"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2019.04.005","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic trials of biologics in primary biliary cholangitis: An open label study of abatacept and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2019.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}